-
State laws passed in the name of patient safety may straddle infection prevention programs with mandates that ultimately are counterproductive, an infection preventionist warned recently in Fort Lauderdale, FL, at the annual conference of the Association for Prevention of Infection Control and Epidemiology (APIC).
-
Ah, the good old days when infections were classified as "nosocomial" (hospital-acquired) or not. There wasn't anything else but "we didn't do this thing" or "yes, this is our infection because we gave this to this person at our hospital."
-
With the move to "targeting zero" infections and abandoning benchmark ranges comes a new role for the infection preventionists: agent of change.
-
Aspirin reduces the risk for myocardial infarction in men ages 45-79 and for stroke in women ages 55-79; however, its use must be balanced against the increased risk of serious bleeding events in each individual patient.
-
Group visits of diabetic patients have the power to foster lifestyle change, improve the control of diabetes and related cardiovascular risk factors, and lower health care costs.
-
Bromocriptine, a dopamine receptor agonist initially approved in 1978 as Parlodel®, has been approved for the treating type 2 diabetes mellitus. The drug is marketed as a quick release formulation by VeroScience LLC as Cycloset™.
-
CT colonography is a screening tool that appears to be reasonably good at identifying colorectal cancer in asymptomatic patients at increased risk for colorectal cancer when compared to colonoscopy. Increased risk is defined as those with a family history of advanced neoplasia in first-degree relatives, personal history of colorectal adenomas, or positive results from fecal occult blood tests (FOBTs).
-
When using an NSAID, a physician must weigh the anticipated therapeutic benefits and assess the potential risks from both the cardiovascular and gastrointestinal perspectives, and the final therapeutic decision should be individualized.
-
Aspirin reduces the risk for myocardial infarction in men ages 45-79 and for stroke in women ages 55-79; however, its use must be balanced against the increased risk of serious bleeding events in each individual patient.
-
